Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AC Immune SA ( (ACIU) ) just unveiled an announcement.
AC Immune SA released its interim financial results for the three and six months ending June 30, 2025, reporting a significant operating loss compared to the previous year. Despite an increase in contract revenue, the company faced substantial operating expenses, leading to a net loss for the period, which may impact its financial stability and investor confidence.
The most recent analyst rating on (ACIU) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on AC Immune SA stock, see the ACIU Stock Forecast page.
Spark’s Take on ACIU Stock
According to Spark, TipRanks’ AI Analyst, ACIU is a Neutral.
AC Immune SA’s stock score is driven by positive short-term technical momentum, but is constrained by persistent net losses and valuation concerns. The stable balance sheet and improved cash flow are encouraging, but the lack of profitability weighs heavily on the overall score.
To see Spark’s full report on ACIU stock, click here.
More about AC Immune SA
AC Immune SA is a Swiss-based biopharmaceutical company focused on developing precision medicine for neurodegenerative diseases. The company specializes in creating vaccines, antibodies, and diagnostics aimed at treating conditions like Alzheimer’s disease.
Average Trading Volume: 131,945
Technical Sentiment Signal: Sell
Current Market Cap: $209.8M
For an in-depth examination of ACIU stock, go to TipRanks’ Overview page.